A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism
Creators
- 1. Neurodegeneration Imaging Group, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London (United Kingdom)
Description
To systematically review the previous studies and current status of positron emission tomography (PET) molecular imaging research in atypical parkinsonism. MEDLINE, ISI Web of Science, Cochrane Library, and Scopus electronic databases were searched for articles published until 29th March 2016 and included brain PET studies in progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and corticobasal syndrome (CBS). Only articles published in English and in peer-reviewed journals were included in this review. Case-reports, reviews, and non-human studies were excluded. Seventy-seven PET studies investigating the dopaminergic system, glucose metabolism, microglial activation, hyperphosphorilated tau, opioid receptors, the cholinergic system, and GABAA receptors in PSP, MSA, and CBS patients were included in this review. Disease-specific patterns of reduced glucose metabolism have shown higher accuracy than dopaminergic imaging techniques to distinguish between parkinsonian syndromes. Microglial activation has been found in all forms of atypical parkinsonism and reflects the known distribution of neuropathologic changes in these disorders. Opioid receptors are decreased in the striatum of PSP and MSA patients. Subcortical cholinergic dysfunction was more severe in MSA and PSP than Parkinson's disease patients although no significant changes in cortical cholinergic receptors were seen in PSP with cognitive impairment. GABAA receptors were decreased in metabolically affected cortical and subcortical regions in PSP patients. PET molecular imaging has provided valuable insight for understanding the mechanisms underlying atypical parkinsonism. Changes at a molecular level occur early in the course of these neurodegenerative diseases and PET imaging provides the means to aid differential diagnosis, monitor disease progression, identify of novel targets for pharmacotherapy, and monitor response to new treatments. (orig.)
Availability note (English)
Available from: http://dx.doi.org/10.1007/s00259-016-3464-8Additional details
Identifiers
Publishing Information
- Journal Title
- European Journal of Nuclear Medicine and Molecular Imaging
- Journal Volume
- 43
- Journal Issue
- 12
- Journal Page Range
- p. 2244-2254
- ISSN
- 1619-7070
INIS
- Country of Publication
- Germany
- Country of Input or Organization
- Germany
- INIS RN
- 47117019
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Resource subtype / Literary indicator
- Numerical Data
- Descriptors DEI
- BIOLOGICAL MARKERS; CARBON 11; CEREBRUM; CHOLINE; COMPILED DATA; COMPUTERIZED TOMOGRAPHY; DOPAMINE; ESERINE; FLUORINE 18; FLUORODEOXYGLUCOSE; METABOLISM; NERVOUS SYSTEM DISEASES; NEUROLOGY; POSITRON COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; THERAPY; UPTAKE
- Descriptors DEC
- ALCOHOLS; ALKALOIDS; AMINES; AMMONIUM COMPOUNDS; ANTIMETABOLITES; AROMATICS; AUTONOMIC NERVOUS SYSTEM AGENTS; BETA DECAY RADIOISOTOPES; BETA-PLUS DECAY RADIOISOTOPES; BODY; BRAIN; CARBON ISOTOPES; CARDIOTONICS; CARDIOVASCULAR AGENTS; CENTRAL NERVOUS SYSTEM; COMPUTERIZED TOMOGRAPHY; DATA; DIAGNOSTIC TECHNIQUES; DISEASES; DRUGS; EMISSION COMPUTED TOMOGRAPHY; EVEN-ODD NUCLEI; FLUORINE ISOTOPES; HOURS LIVING RADIOISOTOPES; HYDROXY COMPOUNDS; INFORMATION; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; LABELLED COMPOUNDS; LIGHT NUCLEI; LIPOTROPIC FACTORS; MATERIALS; MEDICINE; MINUTES LIVING RADIOISOTOPES; NANOSECONDS LIVING RADIOISOTOPES; NERVOUS SYSTEM; NEUROREGULATORS; NUCLEI; NUMERICAL DATA; ODD-ODD NUCLEI; ORGANIC COMPOUNDS; ORGANS; PARASYMPATHOMIMETICS; PHENOLS; POLYPHENOLS; QUATERNARY AMMONIUM COMPOUNDS; RADIOACTIVE MATERIALS; RADIOISOTOPES; SYMPATHOMIMETICS; TOMOGRAPHY